I

Innate Pharma SA

D

IPHA

USD

-0.05

(-2.3041%)

Market Closed

97.000

حجم التداول

-0.67

الربح لكل سهم

-

العائد الربحي

-4.537507

P/E

171,615,657.84

حجم السوق

اليوم

-2.3041%

1 اسبوع

-10.549%

1 شهر

-4.933%

6 اشهر

-12.397%

12 اشهر

-27.768%

بداية السنة

-24.286%

كل الوقت

-64.489%

أصول ذات صلة

Title:
Innate Pharma SA

Sector:

Healthcare

Industry:

Biotechnology

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

هل تحتاج مساعدة او لديك استفسار؟

تواصل معنا